Hikma

News

SCOTUS backs generic firm Hikma in skinny label dispute

SCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.

News

'Skinny' generic Vascepa label case reaches US Supreme Court

SCOTUS has agreed to hear a patent dispute between Amarin and Hikma that could have implications for 'skinny labels' used by generic manufacturers.

News

Generic drugmaker Hikma pledges $1bn in US investment

With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.

News

Jazz pays $145m to resolve Xyrem antitrust disputes

Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.

News

FDA approves flurry of drugs ahead of holiday season

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.

News

Hikma will pay $150m in US opioid settlement

Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could al

SCOTUS backs generic firm Hikma in skinny label dispute

'Skinny' generic Vascepa label case reaches US Supreme Court

Generic drugmaker Hikma pledges $1bn in US investment

Jazz pays $145m to resolve Xyrem antitrust disputes

FDA approves flurry of drugs ahead of holiday season

Hikma will pay $150m in US opioid settlement

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Hikma

Editor's Picks